OKUR — Onkure Therapeutics Share Price
0.000.00%
Last trade - 00:00- $33.60m
- -$77.16m
- 27
- 53
- 22
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.32 | ||
| Price to Tang. Book | 0.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.11% | ||
| Return on Equity | -54.74% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 0.5 | 0.67 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Directors
- Mike Grey CHM
- Gregory Flesher PRE
- Niall O'donnell CFD (48)
- Vineet Jindal CFO
- Lynn Purkins VOP
- Alejandro Dorenbaum OTH
- Ashley Hall OTH (49)
- Paul Hoelscher DRC (56)
- Lon Cardon IND
- Eric Dube IND (48)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 22nd, 2014
- Public Since
- April 9th, 2021
- No. of Shareholders
- 60
- No. of Employees
- 46
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 13,441,875
- Address
- 6707 Winchester Circle, Suite 400, BOULDER, 80301
- Web
- https://onkuretherapeutics.com/
- Phone
- +1 7203072892
- Auditors
- KPMG LLP
Upcoming Events for OKUR
Q2 2025 Onkure Therapeutics Inc Earnings Release
Similar to OKUR
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Onkure Therapeutics share price?
As of Today at 22:28 UTC, shares in Onkure Therapeutics are trading at $2.50. This share price information is delayed by 15 minutes.
How has the Onkure Therapeutics share price performed this year?
Shares in Onkure Therapeutics last closed at $2.50 and the price had moved by -85.55% over the past 365 days. In terms of relative price strength the Onkure Therapeutics share price has underperformed the S&P500 Index by -86.97% over the past year.
What are the analyst and broker recommendations for Onkure Therapeutics?
The overall consensus recommendation for Onkure Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Onkure Therapeutics dividend yield?
Onkure Therapeutics does not currently pay a dividend.
Does Onkure Therapeutics pay a dividend?
Onkure Therapeutics does not currently pay a dividend.
When does Onkure Therapeutics next pay dividends?
Onkure Therapeutics does not currently pay a dividend.
How do I buy Onkure Therapeutics shares?
To buy shares in Onkure Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Onkure Therapeutics?
As of the previous close price of $2.50, shares in Onkure Therapeutics had a market capitalisation of $33.60m.
Where are Onkure Therapeutics shares listed?
Here are the trading details for Onkure Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: OKUR
What kind of share is Onkure Therapeutics?
Based on an overall assessment of its quality, value and momentum Onkure Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Onkure Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Onkure Therapeutics is $32.00. That is 1180% above the last closing price of $2.50.
Analysts covering Onkure Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$5.19 for the next financial year.
Find out moreWhat is the trend in the Onkure Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Onkure Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -84.58%.
As of the last closing price of $2.50, shares in Onkure Therapeutics were trading -76.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Onkure Therapeutics PE Ratio?
The Onkure Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Onkure Therapeutics?
Onkure Therapeutics' management team is headed by:
- Mike Grey - CHM
- Gregory Flesher - PRE
- Niall O'donnell - CFD
- Vineet Jindal - CFO
- Lynn Purkins - VOP
- Alejandro Dorenbaum - OTH
- Ashley Hall - OTH
- Paul Hoelscher - DRC
- Lon Cardon - IND
- Eric Dube - IND